title: Is maternal use of selective serotonin reuptake inhibitors in the third trimester of pregnancy harmful to neonates?
authors.affiliation: Motherisk Program, The Hospital for Sick Children and University of Toronto, Toronto, Ont. gkoren@sickkids.ca
authors.forename: Gideon
authors.initials: G
authors.lastname: Koren
authors.forename: Doreen
authors.initials: D
authors.lastname: Matsui
authors.forename: Adrienne
authors.initials: A
authors.lastname: Einarson
authors.forename: David
authors.initials: D
authors.lastname: Knoppert
authors.forename: Meir
authors.initials: M
authors.lastname: Steiner
mesh_terms: D000328:Adult; D003863:Depression / Q000188:drug therapy*; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D009357:Neonatal Abstinence Syndrome; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy* / Q000523:psychology*; D011263:Pregnancy Trimester, Third; D012307:Risk Factors; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects* / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D017367:Selective Serotonin Reuptake Inhibitors